$SUPN SEC Filings

On October 20, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) terminated the UBS Credit Line Agreement, dated as of February 8, 2023 (the “UBS Credit Line”), between the Company and UBS Bank USA (the “Bank”), which established an u...

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO

ROCKVILLE, Md., October 19, 2026 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced ...

On October 15, 2026 Supernus Pharmaceuticals, Inc. (the “Company”) held a special meeting of its stockholders (the “Special Meeting”). The definitive proxy statement pertaining to the Special Meeting was previously filed by the Company w...

Received 29,849 shares by exercise or conversion · Gave up 12,642 shares to cover exercise price or tax ($589K)

Received 750 shares by exercise or conversion · Gave up 363 shares to cover exercise price or tax ($16.9K)

Received 2,500 shares by exercise or conversion · Gave up 1,158 shares to cover exercise price or tax ($53.9K)

Received 1,650 shares by exercise or conversion · Gave up 797 shares to cover exercise price or tax ($37.1K)

Received 1,250 shares by exercise or conversion · Gave up 604 shares to cover exercise price or tax ($28.1K)